Global Primary Biliary Cholangitis (PBC) It’s Market– Industry Trends and Forecast to 2027

Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027

Wiseguyreports.Com Adds "Primary Biliary Cholangitis (PBC) - Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2027" To Its Research Database.

Description:

DelveInsight’s ‘Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Primary Biliary Cholangitis (PBC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Primary Biliary Cholangitis (PBC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Primary Biliary Cholangitis (PBC) - Disease Understanding and Treatment Algorithm

Primary Biliary Cholangitis (PBC) is a chronic, progressive liver disorder that mostly affects women and usually appears during middle age. PBC leads to inflammation and scarring of the small bile ducts. If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure. PBC is divided into four stages with stage 1 being early disease, where this is no significant scarring, to stage 4, which is defined by cirrhosis.

The DelveInsight Primary Biliary Cholangitis market report gives the thorough understanding of the Primary Biliary Cholangitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Primary Biliary Cholangitis in the US, Europe, and Japan.

Primary Biliary Cholangitis Epidemiology

The Primary Biliary Cholangitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Gender Specific Prevalence, and Diagnosed and Treatable Prevalence] scenario of Primary Biliary Cholangitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to American Association for the Study of Liver Diseases (AASLD), in 2016, the prevalence of PBC in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 persons. As per one study conducted by Daniel S. Smyk (February 2012), approximately 7–11% of PBC patients are males.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3320970-primary-biliary-cholangitis-pbc-market-insights-epidemiology-and

Primary Biliary Cholangitis Drug Chapters

This segment of the Primary Biliary Cholangitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently there is no cure for the treatment for PBC, yet medications are available to slow the progression of disease and prevent complications. Only two FDA approved drugs, Ursodeoxycholic acid (UDCA) and Obeticholic acid are available in market to reduce cirrhosis progression. UDCA doesn't cure primary biliary cholangitis, but it improves liver function and reduce liver scarring.

Primary Biliary Cholangitis Market Outlook

The Primary Biliary Cholangitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

There are different potential drug candidates in the clinical trials for the PBC treatment. Upcoming therapies such as Seladelpar (CymaBay Therapeutics), FFP104 (Fast Forward Pharmaceuticals), Etrasimod (Arena Pharmaceuticals), EDP-305 (Enanta Pharmaceuticals) etc. will significantly impact the PBC market during the study period (2016-2027).

Primary Biliary Cholangitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

• p>

Primary Biliary Cholangitis Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Download Detail Report@ https://www.wiseguyreports.com/reports/3320970-primary-biliary-cholangitis-pbc-market-insights-epidemiology-and

Table of Content

1. Report Introduction

2. Primary Biliary Cholangitis (PBC) Market Overview at a Glance

   2.1. 7 Major Market Size of Primary Biliary Cholangitis (PBC) in 2017

   2.2. 7 Major Market Size of Primary Biliary Cholangitis (PBC) in 2027

3. Disease Background and Overview: Primary Biliary Cholangitis (PBC)

   3.1. Introduction

   3.2. Causes

   3.3. Pathophysiology

   3.4. Symptoms

   3.5. Risk Factor

   3.6. Diagnosis

4. Epidemiology and Patient Population

   4.1. Assumptions and Caveats

   4.2. 7MM Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   4.3. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   4.4. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

5. Primary Biliary Cholangitis (PBC): Country- Wise Epidemiology

   5.1. United States

   5.1.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   5.1.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   5.1.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

   5.2. EU-5

   5.2.1. Germany

   5.2.1.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   5.2.1.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   5.2.1.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

   5.2.2. France

   5.2.2.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   5.2.2.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   5.2.2.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

   5.2.3. Italy

   5.2.3.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   5.2.3.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   5.2.3.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

   5.2.4. Spain

   5.2.4.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   5.2.4.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   5.2.4.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

   5.2.5. United Kingdom

   5.2.5.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   5.2.5.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   5.2.5.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

   5.3. Japan

   5.3.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)

   5.3.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)

   5.3.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)

Continued………..

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Name: Saurabh Sinha Email: Saurabh.Sinha@Wiseguyreports.Com Company: Wise Guy Research Consultants Pvt Ltd 841 198 5042